Literature DB >> 27594190

Potentially Curable Cancers of the Esophagus and Stomach.

Elena Elimova1, Dilsa Mizrak Kaya2, Kazuto Harada2, Jaffer A Ajani3.   

Abstract

Gastric and gastroesophageal adenocarcinomas continue to be a major health burden globally and collectively represent the third leading cause of cancer death. Among patients with metastatic disease, most die of their cancer because of the limited number of modestly effective treatment regimens available today. The progress against these cancers has been slow compared with many other solid tumors despite many attempts. In-depth molecular profiling has also not been completed. Even when these cancers are localized, they impose considerable challenges for the patient, relatives, and treatment team alike. Localized gastric or gastroesophageal cancer is best managed with a multidisciplinary approach. This review focuses on the management of localized cancers by reviewing the current literature and explaining certain principles that help guide therapy for these patients. The future, however, will afford numerous opportunities, including exploitation of initial data from The Cancer Genome Atlas, to identify novel targets and drugs, harness the prowess of the immune system, and customize therapy for each patient.
Copyright © 2016 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27594190      PMCID: PMC5712474          DOI: 10.1016/j.mayocp.2016.07.018

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  95 in total

1.  Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.

Authors:  Akira Tsuburaya; Kazuhiro Yoshida; Michiya Kobayashi; Shigefumi Yoshino; Masazumi Takahashi; Nobuhiro Takiguchi; Kazuaki Tanabe; Naoto Takahashi; Hiroshi Imamura; Naokuni Tatsumoto; Akinori Hara; Kazuhiro Nishikawa; Ryoji Fukushima; Isao Nozaki; Hiroshi Kojima; Yumi Miyashita; Koji Oba; Marc Buyse; Satoshi Morita; Junichi Sakamoto
Journal:  Lancet Oncol       Date:  2014-06-18       Impact factor: 41.316

2.  Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy.

Authors:  Akihiro Suzuki; Lianchun Xiao; Yuki Hayashi; Homer A Macapinlac; James Welsh; Steven H Lin; Jeffrey H Lee; Manoop S Bhutani; Dipen M Maru; Wayne L Hofstetter; Stephen G Swisher; Jaffer A Ajani
Journal:  Cancer       Date:  2011-03-31       Impact factor: 6.860

3.  Defining cure for esophageal cancer: analysis of actual 5-year survivors following esophagectomy.

Authors:  Jodi Hirst; Bernard Mark Smithers; David C Gotley; Janine Thomas; Andrew Barbour
Journal:  Ann Surg Oncol       Date:  2011-01-07       Impact factor: 5.344

4.  Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.

Authors:  Yung-Jue Bang; Young-Woo Kim; Han-Kwang Yang; Hyun Cheol Chung; Young-Kyu Park; Kyung Hee Lee; Keun-Wook Lee; Yong Ho Kim; Sang-Ik Noh; Jae Yong Cho; Young Jae Mok; Yeul Hong Kim; Jiafu Ji; Ta-Sen Yeh; Peter Button; Florin Sirzén; Sung Hoon Noh
Journal:  Lancet       Date:  2012-01-07       Impact factor: 79.321

5.  Treatment trends, risk of lymph node metastasis, and outcomes for localized esophageal cancer.

Authors:  Ryan P Merkow; Karl Y Bilimoria; Rajesh N Keswani; Jeanette Chung; Karen L Sherman; Lawrence M Knab; Mitchell C Posner; David J Bentrem
Journal:  J Natl Cancer Inst       Date:  2014-07-16       Impact factor: 13.506

6.  Gastric Lgr5(+) stem cells are the cellular origin of invasive intestinal-type gastric cancer in mice.

Authors:  Xiu-Bin Li; Guan Yang; Liang Zhu; Yu-Ling Tang; Chong Zhang; Zhenyu Ju; Xiao Yang; Yan Teng
Journal:  Cell Res       Date:  2016-04-19       Impact factor: 25.617

7.  Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.

Authors:  David P Kelsen; Katryn A Winter; Leonard L Gunderson; Joanne Mortimer; Norman C Estes; Daniel G Haller; Jaffer A Ajani; Walter Kocha; Bruce D Minsky; Jack A Roth; Christopher G Willett
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

Review 8.  State of the art management of metastatic gastroesophageal cancer.

Authors:  Adrian G Murphy; David Lynch; Ronan J Kelly
Journal:  Ann Transl Med       Date:  2015-09

9.  Hospital volume, proportion resected and mortality from oesophageal and gastric cancer: a population-based study in England, 2004-2008.

Authors:  Victoria H Coupland; Jesper Lagergren; Margreet Lüchtenborg; Ruth H Jack; William Allum; Lars Holmberg; George B Hanna; Neil Pearce; Henrik Møller
Journal:  Gut       Date:  2012-10-19       Impact factor: 23.059

10.  Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity.

Authors:  Austin M Dulak; Petar Stojanov; Shouyong Peng; Michael S Lawrence; Cameron Fox; Chip Stewart; Santhoshi Bandla; Yu Imamura; Steven E Schumacher; Erica Shefler; Aaron McKenna; Scott L Carter; Kristian Cibulskis; Andrey Sivachenko; Gordon Saksena; Douglas Voet; Alex H Ramos; Daniel Auclair; Kristin Thompson; Carrie Sougnez; Robert C Onofrio; Candace Guiducci; Rameen Beroukhim; Zhongren Zhou; Lin Lin; Jules Lin; Rishindra Reddy; Andrew Chang; Rodney Landrenau; Arjun Pennathur; Shuji Ogino; James D Luketich; Todd R Golub; Stacey B Gabriel; Eric S Lander; David G Beer; Tony E Godfrey; Gad Getz; Adam J Bass
Journal:  Nat Genet       Date:  2013-03-24       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.